Clinical Trial Update: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of Optune's tumor treating fields therapy with Bevacizumab for patients with recurrent or progressive Grade II or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Grade Ii Meningioma
• Grade Iii Meningioma
• Meningioma
• Supratentorial Meningioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• OPTUNE

Snippet

Sponsor: Northwestern University | Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma | Phase 2 | Status: RECRUITING